tiprankstipranks
Trending News
More News >

Anteris Technologies Achieves Key Milestone in Cardiac Care

Story Highlights
Anteris Technologies Achieves Key Milestone in Cardiac Care

Confident Investing Starts Here:

Anteris Technologies Global Corp. ( (AVR) ) has issued an announcement.

On March 31, 2025, Anteris Technologies Global Corp. announced a significant clinical milestone, having treated over 100 patients with its DurAVR® Transcatheter Heart Valve (THV). This achievement underscores the company’s commitment to revolutionizing cardiac care for patients with severe aortic stenosis. The milestone marks a pivotal moment for Anteris as it prepares to commence the DurAVR® THV Pivotal Trial in the third quarter of 2025, pending FDA approval. The company’s progress highlights the potential of the DurAVR® THV to redefine success in aortic stenosis treatment, offering exceptional hemodynamic performance and safety, with no valve or cardiovascular-related mortality reported at one year.

More about Anteris Technologies Global Corp.

Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices to restore healthy heart function. Based in Australia with a significant presence in Minneapolis, USA, the company specializes in treating structural heart disease, particularly aortic stenosis, with its lead product, the DurAVR® Transcatheter Heart Valve (THV).

YTD Price Performance: -31.53%

Average Trading Volume: 182,976

For detailed information about AVR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App